Penn Medicine Partners With Cost Plus Drug Company to Bolster Access to Generic Drugs and Cut Their Costs

The Cost Plus Marketplace is intended to provide healthcare purchasers with transparently priced medications.

Penn Medicine is partnering with Mark Cuban’s Cost Plus Drug Company in order to “secure the top 100 most frequently dispensed generic drugs—such as antibiotics, cancer treatments, blood thinners, and asthma medications—from the company for the health system’s vast retail pharmacy network.”

The Cost Plus Marketplace was “developed to provide healthcare business purchasers with transparently priced medications.” Its aim is to eliminate certain mark-ups on common generic medications.

Penn Medicine pharmacies are “located inside all Penn Medicine hospitals and multi-specialty centers.” Cost Plus’s model will possibly help “ensure continued access” to medications during future shortages. Penn Medicine’s integrated pharmacy system also allows for “complete integration of drug information within patients’ electronic medical records and easy connectivity between providers and pharmacists who monitor for potential drug interactions.”

This large purchasing agreement will also “help decrease carbon emissions through less shipping and packaging waste.”

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates